Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

291 views

Visitors from

US 53%·

AU 34%·

IN 7%·

GB 2%·

HK 1%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

BD Earnings: What To Look For From BDX

February 07, 2026 at 22:03 PM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

BDX Cover Image

Medical technology company Becton, Dickinson and Company (NYSE: BDX) will be reporting results this Monday before the bell. Here’s what to expect.

BD met analysts’ revenue expectations last quarter, reporting revenues of $5.89 billion, up 8.3% year on year. It was a mixed quarter for the company, with a narrow beat of analysts’ EPS estimates but revenue in line with analysts’ estimates.

Is BD a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting BD’s revenue to be flat year on year at $5.15 billion, slowing from the 9.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.81 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BD has missed Wall Street’s revenue estimates four times over the last two years.

Looking at BD’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. STERIS delivered year-on-year revenue growth of 9.2%, beating analysts’ expectations by 1.1%, and CONMED reported revenues up 7.9%, topping estimates by 1.7%. STERIS traded down 7.7% following the results while CONMED was also down 3.6%.

Read our full analysis of STERIS’s results here and CONMED’s results here.

Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.2% on average over the last month. BD is up 3.6% during the same time and is heading into earnings with an average analyst price target of $211.92 (compared to the current share price of $206.89).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article